NASDAQ:LSB Lakeshore Biopharma (LSB) Stock Price, News & Analysis $4.01 +0.70 (+21.15%) (As of 10/8/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends About Lakeshore Biopharma Stock (NASDAQ:LSB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lakeshore Biopharma alerts:Sign Up Key Stats Today's Range$3.31▼$4.1350-Day Range$0.40▼$5.4552-Week Range$3.20▼$11.20Volume104,350 shsAverage Volume13,708 shsMarket Capitalization$373.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewLakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 2002 and is based in Beijing, China.Read More… [SHOCKING] Crypto Document Leak… (Ad)The crypto market waits for no one. And my team of experts and I believe that a BIG move is right around the corner. That's why we're offering you instant access to the game-changing book that's transforming average investors into massive crypto successes.Download your digital copy now Lakeshore Biopharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks7th Percentile Overall ScoreLSB MarketRank™: Lakeshore Biopharma scored higher than 7% of companies evaluated by MarketBeat, and ranked 966th out of 994 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Lakeshore Biopharma.Read more about Lakeshore Biopharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioLakeshore Biopharma has a P/B Ratio of 4.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lakeshore Biopharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.11% of the float of Lakeshore Biopharma has been sold short.Short Interest Ratio / Days to CoverLakeshore Biopharma has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lakeshore Biopharma has recently increased by 38.54%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLakeshore Biopharma does not currently pay a dividend.Dividend GrowthLakeshore Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.11% of the float of Lakeshore Biopharma has been sold short.Short Interest Ratio / Days to CoverLakeshore Biopharma has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lakeshore Biopharma has recently increased by 38.54%, indicating that investor sentiment is decreasing significantly. News and Social Media2.1 / 5News Sentiment-0.27 News SentimentLakeshore Biopharma has a news sentiment score of -0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Lakeshore Biopharma this week, compared to 1 article on an average week.Search Interest3 people have searched for LSB on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Lakeshore Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lakeshore Biopharma insiders have not sold or bought any company stock.Percentage Held by Institutions52.64% of the stock of Lakeshore Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lakeshore Biopharma's insider trading history. Receive LSB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lakeshore Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address LSB Stock News HeadlinesLakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial GuidanceOctober 8 at 8:30 AM | prnewswire.comLakeshore Biopharma (NASDAQ:LSB) Shares Gap Down - Here's WhyOctober 6 at 3:27 AM | americanbankingnews.comMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.October 8, 2024 | Paradigm Press (Ad)Lakeshore Biopharma (NASDAQ:LSB) Hits New 12-Month High - Time to Buy?October 3, 2024 | americanbankingnews.comLakeShore Biopharma Co., Ltd (H6Z.F)October 2, 2024 | au.finance.yahoo.comLakeshore Biopharma (NASDAQ:LSB) Stock Price Up 1.1%September 28, 2024 | americanbankingnews.comLakeShore Biopharma Announces Results of Extraordinary General Meeting on Share ConsolidationSeptember 27, 2024 | prnewswire.comLakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024September 10, 2024 | prnewswire.comSee More Headlines LSB Stock Analysis - Frequently Asked Questions How have LSB shares performed this year? Lakeshore Biopharma's stock was trading at $0.4703 at the beginning of the year. Since then, LSB shares have increased by 752.6% and is now trading at $4.01. View the best growth stocks for 2024 here. When did Lakeshore Biopharma's stock split? Lakeshore Biopharma's stock reverse split on Friday, October 4th 2024. The 1-10 reverse split was announced on Friday, September 27th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Lakeshore Biopharma? Shares of LSB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Today10/08/2024Next Earnings (Estimated)1/27/2025Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LSB Previous SymbolNASDAQ:LSB CUSIPN/A CIK1946399 WebN/A Phone17327133678FaxN/AEmployees773Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.17 Current Ratio1.13 Quick Ratio0.87 Sales & Book Value Annual Sales$573.42 million Price / Sales0.65 Cash FlowN/A Price / Cash FlowN/A Book Value$0.89 per share Price / Book4.51Miscellaneous Outstanding Shares93,058,000Free FloatN/AMarket Cap$373.16 million OptionableN/A Beta0.60 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:LSB) was last updated on 10/8/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lakeshore Biopharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lakeshore Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
